Nature Communications (May 2020)
Immunogenicity of a DNA vaccine candidate for COVID-19
- Trevor R. F. Smith,
- Ami Patel,
- Stephanie Ramos,
- Dustin Elwood,
- Xizhou Zhu,
- Jian Yan,
- Ebony N. Gary,
- Susanne N. Walker,
- Katherine Schultheis,
- Mansi Purwar,
- Ziyang Xu,
- Jewell Walters,
- Pratik Bhojnagarwala,
- Maria Yang,
- Neethu Chokkalingam,
- Patrick Pezzoli,
- Elizabeth Parzych,
- Emma L. Reuschel,
- Arthur Doan,
- Nicholas Tursi,
- Miguel Vasquez,
- Jihae Choi,
- Edgar Tello-Ruiz,
- Igor Maricic,
- Mamadou A. Bah,
- Yuanhan Wu,
- Dinah Amante,
- Daniel H. Park,
- Yaya Dia,
- Ali Raza Ali,
- Faraz I. Zaidi,
- Alison Generotti,
- Kevin Y. Kim,
- Timothy A. Herring,
- Sophia Reeder,
- Viviane M. Andrade,
- Karen Buttigieg,
- Gan Zhao,
- Jiun-Ming Wu,
- Dan Li,
- Linlin Bao,
- Jiangning Liu,
- Wei Deng,
- Chuan Qin,
- Ami Shah Brown,
- Makan Khoshnejad,
- Nianshuang Wang,
- Jacqueline Chu,
- Daniel Wrapp,
- Jason S. McLellan,
- Kar Muthumani,
- Bin Wang,
- Miles W. Carroll,
- J. Joseph Kim,
- Jean Boyer,
- Daniel W. Kulp,
- Laurent M. P. F. Humeau,
- David B. Weiner,
- Kate E. Broderick
Affiliations
- Trevor R. F. Smith
- Inovio Pharmaceuticals, Plymouth Meeting
- Ami Patel
- Vaccine and Immunotherapy Center, Wistar Institute
- Stephanie Ramos
- Inovio Pharmaceuticals, Plymouth Meeting
- Dustin Elwood
- Inovio Pharmaceuticals, Plymouth Meeting
- Xizhou Zhu
- Vaccine and Immunotherapy Center, Wistar Institute
- Jian Yan
- Inovio Pharmaceuticals, Plymouth Meeting
- Ebony N. Gary
- Vaccine and Immunotherapy Center, Wistar Institute
- Susanne N. Walker
- Vaccine and Immunotherapy Center, Wistar Institute
- Katherine Schultheis
- Inovio Pharmaceuticals, Plymouth Meeting
- Mansi Purwar
- Vaccine and Immunotherapy Center, Wistar Institute
- Ziyang Xu
- Vaccine and Immunotherapy Center, Wistar Institute
- Jewell Walters
- Inovio Pharmaceuticals, Plymouth Meeting
- Pratik Bhojnagarwala
- Vaccine and Immunotherapy Center, Wistar Institute
- Maria Yang
- Inovio Pharmaceuticals, Plymouth Meeting
- Neethu Chokkalingam
- Vaccine and Immunotherapy Center, Wistar Institute
- Patrick Pezzoli
- Inovio Pharmaceuticals, Plymouth Meeting
- Elizabeth Parzych
- Vaccine and Immunotherapy Center, Wistar Institute
- Emma L. Reuschel
- Vaccine and Immunotherapy Center, Wistar Institute
- Arthur Doan
- Inovio Pharmaceuticals, Plymouth Meeting
- Nicholas Tursi
- Vaccine and Immunotherapy Center, Wistar Institute
- Miguel Vasquez
- Inovio Pharmaceuticals, Plymouth Meeting
- Jihae Choi
- Vaccine and Immunotherapy Center, Wistar Institute
- Edgar Tello-Ruiz
- Vaccine and Immunotherapy Center, Wistar Institute
- Igor Maricic
- Inovio Pharmaceuticals, Plymouth Meeting
- Mamadou A. Bah
- Vaccine and Immunotherapy Center, Wistar Institute
- Yuanhan Wu
- Vaccine and Immunotherapy Center, Wistar Institute
- Dinah Amante
- Inovio Pharmaceuticals, Plymouth Meeting
- Daniel H. Park
- Vaccine and Immunotherapy Center, Wistar Institute
- Yaya Dia
- Vaccine and Immunotherapy Center, Wistar Institute
- Ali Raza Ali
- Vaccine and Immunotherapy Center, Wistar Institute
- Faraz I. Zaidi
- Vaccine and Immunotherapy Center, Wistar Institute
- Alison Generotti
- Inovio Pharmaceuticals, Plymouth Meeting
- Kevin Y. Kim
- Vaccine and Immunotherapy Center, Wistar Institute
- Timothy A. Herring
- Inovio Pharmaceuticals, Plymouth Meeting
- Sophia Reeder
- Vaccine and Immunotherapy Center, Wistar Institute
- Viviane M. Andrade
- Inovio Pharmaceuticals, Plymouth Meeting
- Karen Buttigieg
- National Infection Service, Public Health England, Porton Down
- Gan Zhao
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd
- Jiun-Ming Wu
- Advaccine (Suzhou) Biopharmaceuticals Co., Ltd
- Dan Li
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Linlin Bao
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Jiangning Liu
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Wei Deng
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Chuan Qin
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Ami Shah Brown
- Inovio Pharmaceuticals, Plymouth Meeting
- Makan Khoshnejad
- Vaccine and Immunotherapy Center, Wistar Institute
- Nianshuang Wang
- Department of Molecular Biosciences, The University of Texas at Austin
- Jacqueline Chu
- Vaccine and Immunotherapy Center, Wistar Institute
- Daniel Wrapp
- Department of Molecular Biosciences, The University of Texas at Austin
- Jason S. McLellan
- Department of Molecular Biosciences, The University of Texas at Austin
- Kar Muthumani
- Vaccine and Immunotherapy Center, Wistar Institute
- Bin Wang
- Key Laboratory of Medical Molecular Virology of MOH and MOE and Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Fudan University
- Miles W. Carroll
- National Infection Service, Public Health England, Porton Down
- J. Joseph Kim
- Inovio Pharmaceuticals, Plymouth Meeting
- Jean Boyer
- Inovio Pharmaceuticals, Plymouth Meeting
- Daniel W. Kulp
- Vaccine and Immunotherapy Center, Wistar Institute
- Laurent M. P. F. Humeau
- Inovio Pharmaceuticals, Plymouth Meeting
- David B. Weiner
- Vaccine and Immunotherapy Center, Wistar Institute
- Kate E. Broderick
- Inovio Pharmaceuticals, Plymouth Meeting
- DOI
- https://doi.org/10.1038/s41467-020-16505-0
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 13
Abstract
There is currently no licensed SARS-CoV-2 vaccine. Here, the authors generate an optimized DNA vaccine candidate encoding the SARS-CoV-2 spike antigen, demonstrating induction of specific T cells and neutralizing antibody responses in mice and guinea pigs. These initial results support further development of this vaccine candidate.
